Abstract
12P - Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have